N@N

CONCORD, Calif.--([ BUSINESS WIRE ])--Cerus Corporation (NASDAQ:CERS) announced today that Dr. Laurence Corash, chief medical officer, is scheduled to present a corporate update at the Stifel Nicolaus Weisel Healthcare Conference in Boston at 9:45 AM ET on Wednesday, September 5, 2012.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at [ http://www.cerus.com/Investors/Investor-Overview ]. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedicalproducts company focused on commercializing the INTERCEPT Blood System toenhance blood safety. The INTERCEPT system is designed toreduce the risk oftransfusion-transmitted diseases by inactivating a broad range of pathogenssuch as viruses, bacteria and parasites that may be present in donated blood.Thenucleic acid targeting mechanism of action enables INTERCEPT treatment toinactivate established transfusion threats, such as hepatitis B and C, HIV,West Nile virus and bacteria,and is designed to inactivate emerging pathogenssuch as influenza, malaria and dengue. Cerus currently markets and sells theINTERCEPT Blood System for both platelets andplasma in Europe, theCommonwealth of Independent States, the Middle East and selected countries inother regions around the world. The INTERCEPT Blood System for red bloodcellsis in clinical development. See[ http://www.cerus.com ]for more information.

INTERCEPT and the INTERCEPT BloodSystem are trademarks of Cerus Corporation.